On the basis of the most relevant literature results, we describe an overview of our NGS BRCA1 and BRCA2 data of prostate cancer patients’ FFPE samples, and we highlight technical procedures performed and relevant clinical implications. The gene discussed is BRCA2; the disease is prostate carcinoma.